As a leading innovator in the development of tools for the cancer research laboratory, ACEA Biosciences, The Cell Analysis Company, is partnering with the nonprofit Cancer Research Institute (CRI) to proudly support their annual global awareness campaign, Cancer Immunotherapy Month, taking place in June.
To promote the Cancer Research Institute’s global awareness campaign, Cancer Immunotherapy Month, ACEA Biosciences will be participating in the #WearWhite campaign on June 15 and providing an Immunotherapy Research Grant to help scientists in the field of cancer research achieve their goals.
As a leading innovator in the development of tools for the cancer research laboratory, ACEA Biosciences, The Cell Analysis Company, is partnering with the nonprofit Cancer Research Institute (CRI) to proudly support their annual global awareness campaign, Cancer Immunotherapy Month, taking place in June. During last year’s campaign, CRI reached 5 million people and raised $1.5 million in vital cancer research funds. CRI supports the full spectrum of discovery, from lab-to-clinic-to-cure, making maximum impact on the future of cancer treatment. Leading the field of immunology research for 65 years, CRI funds doctors and scientists working to develop immunotherapy as a cure for all cancers. To further advance the field of immunotherapy research, ACEA Biosciences provides technologies to scientists worldwide, which are used to discover groundbreaking treatments that ultimately improve clinical outcomes for patients challenged with cancer.
In celebration of Cancer Immunotherapy Month, ACEA Biosciences will be participating in the #WearWhite campaign on June 15 and providing an Immunotherapy Research Grant to help scientists in the field of cancer research achieve their goals. The research grant winner will be provided access to the xCELLigence® Real Time Cell Analysis (RTCA) SP instrument, consumables, and consultation for up to 6 months. The xCELLigence RTCA instruments dynamically monitor the efficacy of target tumor cell killing by novel therapeutic drugs or other treatments that utilize the body’s own immune system to combat cancer. This technology enables scientists to quantitatively measure the cytotoxic activity of antibodies, genetically engineered CAR-T cells, immune checkpoint inhibitors, and much more. The deadline to apply for the Immunotherapy Research Grant is September 15, 2018.
In addition to the xCELLigence platform, ACEA has created the NovoCyte® and NovoCyte Quanteon™ high performance flow cytometers. Flow cytometry, a powerful analytical instrument for the characterization and analysis of individual cells, has become an essential tool for a variety of immunotherapy applications. These applications include the evaluation of early biomarkers for predicting response to treatments and characterizing the quantity and quality of immune cells.
About xCELLigence Real Time Cell Analysis (RTCA) Instruments
The xCELLigence RTCA instruments use noninvasive electrical impedance monitoring to quantify cell proliferation, morphology change, and attachment quality in a label-free, real-time manner. This impedance signal is measured automatically, at an interval defined by the user, and provides an extremely sensitive readout of cell behavior. The xCELLigence RTCA instruments are being used in both academia and industry for applications ranging from cancer immunotherapy, cardiotoxicity and drug discovery.
About NovoCyte Flow Cytometers
The NovoCyte and NovoCyte Quanteon™ are high performance yet budget-friendly benchtop flow cytometers that are accessible to all levels of users. With one to three different laser options and a highly customizable optical platform, the NovoCyte flow cytometer can be configured for diverse applications and is readily upgradeable over time. The NovoCyte Quanteon flow cytometer provides an expanded set of capabilities that easily accommodates the large, multi-color panels found in today’s highly progressive flow cytometry laboratories. With the NovoCyte Quanteon, scientists have the flexibility to choose from 25 fluorescent channels utilizing four lasers and 25 independent silicon photomultiplier (SiPM) detectors.
About ACEA Biosciences
Founded in 2002, ACEA Biosciences is a pioneer in the development and commercialization of high performance cell analysis platforms for life science research. ACEA’s xCELLigence Real Time Cell Analysis instruments and NovoCyte flow cytometers are used in pre-clinical drug discovery and development, toxicology, safety pharmacology, and basic academic research. More than 2,300 instruments have been placed globally and have been used in more than 1,700 peer reviewed publications.
Follow on Linked In, Twitter, and Facebook
For further information please contact:
ACEA Biosciences, Inc.
Dr. Jeff Xue
Phone: 858-299-8023
email: jxue(at)aceabio(dot)com
